Latest / The Well-Built Life / Mitochondria Miracle: Restoring Vision Through Cell Transplantation
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:10Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:14Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:19Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:24Speaker 1: and let's dive in. So, folks, Today we are diving
- 0:27Speaker 1: into some groundbreaking news in the world of mitochondrial therapy,
- 0:32Speaker 1: a procedure that's showing promise for reversing blindness caused by
- 0:36Speaker 1: optic neuropathy. First, let's set the scene. We have here
- 0:40Speaker 1: a real life story of a 26-year-old woman who was
- 0:44Speaker 1: nearly blind due to an 18-hour brain bleed that led
- 0:48Speaker 1: to bilateral optic neuropathy, a very serious condition where the
- 0:52Speaker 1: nerves that send visual information from the eyes to the
- 0:55Speaker 1: brain are damaged.
- 0:57Speaker 2: Exactly. This is a dramatic example of how quickly optic
- 1:01Speaker 2: neuropathy can progress. And yet, this woman's case is what
- 1:04Speaker 2: I find most intriguing. Dr. David Putrino from the Icahn
- 1:08Speaker 2: School of Medicine at Mount Sinai and his team were
- 1:11Speaker 2: faced with a unique challenge. They had limited time, a
- 1:14Speaker 2: critically ill patient, and no other options. Let's break down
- 1:18Speaker 2: the details of what they did.
- 1:19Speaker 1: Right. The treatment was innovative, to say the least. The
- 1:24Speaker 1: doctors took a muscle biopsy from the patient's thigh, extracted
- 1:28Speaker 1: the mitochondria, and injected them directly into the woman's eyes. Mitochondria,
- 1:34Speaker 1: you will recall, are the powerhouses of cells responsible for
- 1:38Speaker 1: producing ATP, the energy currency for cells. In this case,
- 1:43Speaker 1: these mitochondria were injected with the hope of improving the
- 1:47Speaker 1: survival of the retinal ganglion cells, which are essential for vision.
- 1:51Speaker 1: and particularly vulnerable to metabolic stress.
- 1:55Speaker 2: Precisely. Retinal ganglion cells are the nerve cells that process
- 1:59Speaker 2: visual information, and their health is critical. Typically, once these
- 2:03Speaker 2: cells are damaged, they don't repair themselves, making this a
- 2:07Speaker 2: novel approach. The treatment was performed under emergency expanded access protocols,
- 2:12Speaker 2: allowing for investigational treatments outside of clinical trials. The fact
- 2:17Speaker 2: that the patient's retinal cells began to react to light
- 2:19Speaker 2: within days is a promising sign, at least from a
- 2:23Speaker 2: safety perspective.
- 2:24Speaker 1: It's indeed an interesting step. However, the absence of a
- 2:29Speaker 1: control group in this case means we can't definitively say
- 2:33Speaker 1: whether the mitochondrial therapy is effective. Speaking of which, the
- 2:38Speaker 1: woman's case is more of a proof of concept than
- 2:41Speaker 1: a randomized controlled trial. The researchers acknowledge that while they
- 2:45Speaker 1: have observed some changes, Therese no statistical significance in her
- 2:48Speaker 1: visual acuity. This is a point where we, as health enthusiasts,
- 2:53Speaker 1: need to tread carefully.
- 2:54Speaker 2: Absolutely. The treatment's return of pupillary reactivity and the brain
- 2:59Speaker 2: recording showing organized responses 45 days post. Treatment are significant,
- 3:05Speaker 2: but they also raise several questions. For example, would earlier
- 3:09Speaker 2: intervention have produced more sustained results? This is something researchers
- 3:14Speaker 2: will need to address in future trials. And speaking of
- 3:17Speaker 2: which … The FDA is already working on a protocol
- 3:21Speaker 2: for repeated mitochondrial injections, which could potentially help maintain the benefits.
- 3:26Speaker 1: That's right. This case study opens up a new avenue
- 3:29Speaker 1: for thinking about treating optic neuropathy and related conditions. Instead
- 3:34Speaker 1: of focusing solely on repairing or replacing damaged neurons, the
- 3:38Speaker 1: approach now might be to support the surviving retinal ganglion
- 3:41Speaker 1: cells with a direct energy supply.
- 3:43Speaker 2: This is a.
- 3:44Speaker 1: Shift in paradigm, and it could potentially alter how doctors
- 3:48Speaker 1: approach these issues in the future.
- 3:50Speaker 2: It's fascinating to see how the medical community is responding
- 3:53Speaker 2: to this breakthrough. Looking ahead, future trials will need to
- 3:57Speaker 2: involve more rigorous testing with a broader group of patients
- 4:01Speaker 2: to establish both the efficacy and safety of this treatment.
- 4:04Speaker 2: For now, we can only hope that this research continues
- 4:08Speaker 2: to progress and bring us closer to a treatment that
- 4:11Speaker 2: could literally change someone's life.
- 4:13Speaker 1: Let's delve into the specifics of the mitochondrial extraction process. Dr.
- 4:18Speaker 1: Petrino's team took a biopsy from the patient's thigh muscle.
- 4:22Speaker 1: Can you explain the rationale behind choosing the patient's own
- 4:25Speaker 1: muscle cells for the mitochondria?
- 4:27Speaker 2: Absolutely. They chose autologous mitochondria to ensure a low risk
- 4:32Speaker 2: of immune rejection. The muscle cells from the thigh were
- 4:35Speaker 2: biopsied because they contain a high density of mitochondria, making
- 4:40Speaker 2: them ideal for extracting a sufficient number needed for the treatment.
- 4:43Speaker 1: That's interesting. So... How exactly did the researchers isolate these mitochondria?
- 4:49Speaker 1: Was it a complex process?
- 4:51Speaker 2: Actually, it was quite intricate. The researchers used a combination
- 4:55Speaker 2: of techniques, including mechanical and enzymatic breakdown of the muscle
- 5:00Speaker 2: tissue to release the mitochondria. They also employed specialized equipment
- 5:04Speaker 2: to separate the mitochondria based on size and density. This
- 5:08Speaker 2: step is critical to ensuring the highest purity of the
- 5:11Speaker 2: mitochondria to be injected.
- 5:13Speaker 1: Got it. Now, Can you walk us through the injection process?
- 5:18Speaker 1: What did they do after they isolated the mitochondria?
- 5:21Speaker 2: Sure thing. They injected the purified mitochondria intravitrally, which means
- 5:26Speaker 2: they put them directly into the vitreous fluid of each eye,
- 5:30Speaker 2: 24 hours apart. This method was chosen because the injection site,
- 5:34Speaker 2: the vitreous cavity, is rich in blood vessels. And the
- 5:38Speaker 2: fluid environment is similar to that of the muscle cells,
- 5:41Speaker 2: making it ideal for the mitochondria to take up residence there.
- 5:45Speaker 1: And what were the immediate results? They observed post-injection.
- 5:49Speaker 2: Right away, they noted pupillary reactivity returning in each eye
- 5:53Speaker 2: within days. This was a good sign that the mitochondria
- 5:57Speaker 2: were taking hold and potentially contributing to cell function. However,
- 6:02Speaker 2: the patient's visual acuity remained severely impaired and indicating that
- 6:07Speaker 2: while the immediate physiological response was promising, functional recovery was
- 6:12Speaker 2: not yet evident.
- 6:13Speaker 1: That's a complex mix of good and bad news. What
- 6:17Speaker 1: does this suggest about the timing of intervention and the
- 6:20Speaker 1: potential need for repeated treatments?
- 6:22Speaker 2: Exactly. The case raises important questions. Earlier intervention might indeed
- 6:28Speaker 2: produce more sustained results, especially considering that the patient had
- 6:32Speaker 2: been blind for over two months prior to the treatment.
- 6:35Speaker 2: The team is now working with the FDA to develop
- 6:38Speaker 2: a protocol for repeated mitochondrial injections to potentially solidify the
- 6:42Speaker 2: benefits and see if multiple treatments can enhance visual acuity.
- 6:47Speaker 1: Fascinating. Given these findings, how might this change the way
- 6:51Speaker 1: doctors approach treating conditions like optic neuropathy and glaucoma?
- 6:57Speaker 2: This case study demonstrates a shift in paradigm, moving away
- 7:00Speaker 2: from the goal of repairing or replacing dead neurons. to
- 7:04Speaker 2: focusing on supporting surviving retinal ganglion cells with direct energy supply. Essentially,
- 7:09Speaker 2: it's about providing a direct energy boost to cells that
- 7:13Speaker 2: are still viable, which could be a game changer in
- 7:15Speaker 2: how we treat a wide range of retinal conditions.
- 7:18Speaker 1: That's a big leap in thinking, and it comes with
- 7:21Speaker 1: the understanding that trees still much to learn. What's the
- 7:24Speaker 1: next step for researchers in this field?
- 7:27Speaker 2: Researchers acknowledge that more controlled trials with a larger group
- 7:31Speaker 2: of patients are needed to properly test the efficacy and
- 7:34Speaker 2: safety of this treatment. The current case is insufficient to
- 7:37Speaker 2: prove the treatment's effectiveness, but it does provide strong anecdotal
- 7:41Speaker 2: evidence that warrants further investigation. Future trials will need to
- 7:45Speaker 2: be meticulously designed to ensure that we can gather comprehensive
- 7:49Speaker 2: data that can inform clinical practice.
- 7:52Speaker 1: Let's talk about the patient's recovery in more detail. As
- 7:55Speaker 1: we mentioned, the woman initially showed no response to light,
- 7:59Speaker 1: a clear indication of the severity of her condition. Now,
- 8:04Speaker 1: let's analyze the pupillary reactivity and brain recordings.
- 8:07Speaker 2: Absolutely. Pupillary reactivity can be a critical indicator of neurological function.
- 8:13Speaker 2: In this case, we see the patient's eyes began to
- 8:16Speaker 2: react to light soon after the treatment within just a
- 8:19Speaker 2: few days. This is a promising sign, but it's important
- 8:23Speaker 2: to understand what this really means.
- 8:25Speaker 1: Right. It suggests there might be a communication pathway from
- 8:28Speaker 1: the retina to the brain. But is it enough? The
- 8:32Speaker 1: brain recordings show some organized responses in the visual cortex,
- 8:36Speaker 1: but what does that tell us about the long-term outlook?
- 8:38Speaker 2: Those recordings might indicate that the injected mitochondria are having
- 8:42Speaker 2: an impact. But we need to consider the timing. If
- 8:46Speaker 2: this patient had received treatment sooner, might the results have
- 8:49Speaker 2: been different and more lasting?
- 8:51Speaker 1: Exactly, which brings up an interesting contradiction. The current case
- 8:56Speaker 1: study is a single patient, and it's hard to draw
- 8:59Speaker 1: definitive conclusions. But the retinal ganglion cells rely heavily on
- 9:04Speaker 1: energy from mitochondria. So, if the patient is now able
- 9:08Speaker 1: to perceive shapes and shadows in her left eye, That
- 9:11Speaker 1: might mean some cells are indeed recovering.
- 9:14Speaker 2: That's the exciting part, but it's also where we need
- 9:17Speaker 2: to be cautious. Visual acuity hasn't significantly improved, and the
- 9:22Speaker 2: case is still insufficient to prove efficacy. Still, it does
- 9:26Speaker 2: provide a basis for further investigation.
- 9:29Speaker 1: Agreed. The treatment seems to be showing some preliminary success,
- 9:34Speaker 1: but it underscores the need for more controlled trials. What's
- 9:38Speaker 1: the plan moving forward?
- 9:39Speaker 2: The research team is working on developing a protocol for
- 9:42Speaker 2: repeated mitochondrial injections. They are aiming to sustain these benefits
- 9:47Speaker 2: over time. If what we are seeing now holds, this
- 9:51Speaker 2: could be a game changer, especially for optic neuropathy and
- 9:54Speaker 2: other retinal conditions.
- 9:56Speaker 1: And that brings us to an interesting point. This type
- 9:59Speaker 1: of therapy... focuses on supporting surviving cells rather than simply
- 10:03Speaker 1: trying to repair or replace them. It's a different perspective
- 10:07Speaker 1: on maintaining vision in a way that traditional treatments can't.
- 10:11Speaker 2: Exactly. The goal is to keep those vital retinal ganglion
- 10:15Speaker 2: cells functioning as long as possible. It's a shift in thinking,
- 10:19Speaker 2: and it's exciting to see where this line of research
- 10:21Speaker 2: might lead.
- 10:22Speaker 1: Now, Thomas, let's talk about the timing of intervention. There
- 10:26Speaker 1: is a lot of interest in understanding whether earlier or
- 10:29Speaker 1: later treatment might yield better long-term results.
- 10:32Speaker 2: Absolutely, Rachel. The timing of these interventions is crucial. Historically,
- 10:37Speaker 2: treatments are often administered when the damage is already extensive.
- 10:41Speaker 2: In this case, the patient's optic nerve was severely damaged.
- 10:45Speaker 2: and they hadn't responded to light for two months. But
- 10:49Speaker 2: that raises the question, might earlier intervention have provided more
- 10:53Speaker 2: sustained results after the initial injury?
- 10:55Speaker 1: Exactly. If the treatment could be applied sooner, to ease
- 10:59Speaker 1: a chance of preserving more eye function, the FDA approved
- 11:03Speaker 1: eyedrop vis-temporarily restored near vision in a patient's retina, which
- 11:07Speaker 1: points to the potential of early treatment. But with something
- 11:10Speaker 1: as complex as retinal ganglion cells, it's not just about
- 11:14Speaker 1: the timing. but also the severity and type of damage. Right.
- 11:19Speaker 2: The team behind the mitochondria therapy is working on a
- 11:22Speaker 2: protocol with the FDA for repeated injections. This is to
- 11:26Speaker 2: see if ongoing support can maintain the benefits over time.
- 11:30Speaker 2: What do you think, Thomas, about the potential need for
- 11:33Speaker 2: multiple treatments?
- 11:34Speaker 1: Well, it seems the initial dosages didn't fully restore the
- 11:37Speaker 1: patient's vision. Pupillary responses and brain recordings were positive, but
- 11:43Speaker 1: visual acuity remained severely impaired. This suggests a need for
- 11:47Speaker 1: further interventions. The doctors are exploring whether repeated doses of
- 11:51Speaker 1: healthy mitochondria could help maintain the function of the retinal cells.
- 11:56Speaker 2: Exactly like a steady supply of energy to a plant
- 12:00Speaker 2: to keep it thriving in a harsh environment, put trees
- 12:03Speaker 2: a balance to keep in mind. Overdosing could potentially stress
- 12:07Speaker 2: the cells, or the body might develop an immune response
- 12:11Speaker 2: to these repeated injections. We will need to carefully monitor that. True.
- 12:16Speaker 1: And safety is paramount. The earlier treatment might not only
- 12:19Speaker 1: be more effective, but also safer. Traditional therapies are often invasive,
- 12:25Speaker 1: requiring surgery, and come with their own risks. With mitochondrial therapy,
- 12:31Speaker 1: the goal is to provide a non-invasive, targeted approach. This
- 12:35Speaker 1: could be a game changer for patients who might otherwise
- 12:38Speaker 1: be left with severe visual impairment.
- 12:41Speaker 2: And this is why the future trials with a larger
- 12:43Speaker 2: patient cohort are so critical. We need to prove both
- 12:47Speaker 2: the safety and efficacy of this approach. The current case
- 12:51Speaker 2: is just a stepping stone. It's important to keep pushing
- 12:54Speaker 2: the boundaries of what we can do with mitochondrial therapy,
- 12:57Speaker 2: especially when it comes to addressing conditions like optic neuropathy
- 13:01Speaker 2: and glaucoma.
- 13:02Speaker 1: Agreed. The research here is fascinating, and it's clear that
- 13:06Speaker 1: supporting the surviving cells directly could be a new paradigm
- 13:10Speaker 1: in treating optic neuropathy. For now, we need to maintain
- 13:13Speaker 1: a balanced approach. considering both the potential benefits and the
- 13:18Speaker 1: practicalities of repeated injections. The future of treating optic neuropathy
- 13:22Speaker 1: and other retinal conditions through mitochondrial therapy is both promising
- 13:26Speaker 1: and complex. As the scientific community looks beyond the initial
- 13:31Speaker 1: case studies, what strategic shifts might we see in future
- 13:35Speaker 1: research and clinical applications?
- 13:37Speaker 2: Absolutely, Rachel. The initial success is certainly exciting, but it
- 13:41Speaker 2: also highlights the need for a multifaceted approach. For instance,
- 13:46Speaker 2: with the first patient showing some pupillary responses and brain
- 13:49Speaker 2: recordings indicating some visual information making it to the visual cortex,
- 13:54Speaker 2: even if at a superficial level, how do you predict
- 13:57Speaker 2: researchers might expand on these findings in future studies?
- 14:01Speaker 1: Right, and that's the crucial nuance here. The current case
- 14:04Speaker 1: is indeed a stepping stone, but it also underscores the
- 14:07Speaker 1: importance of continued research. One key question is whether these
- 14:11Speaker 1: initial promising signs can be corroborated with larger-scale, controlled trials.
- 14:17Speaker 1: With the absence of a control group, how might follow-up
- 14:20Speaker 1: studies ensure both safety and efficacy?
- 14:22Speaker 2: Definitely, the safety aspect is paramount. However, from a strategic perspective,
- 14:28Speaker 2: even if the therapy proves not as effective as hoped,
- 14:31Speaker 2: the groundwork laid for understanding retinal cells and their reliance
- 14:35Speaker 2: on mitochondria will be invaluable. How do you think this
- 14:38Speaker 2: might influence the broader landscape of ophthalmology research and patient
- 14:42Speaker 2: care practices?
- 14:43Speaker 1: Well, Thomas, think about how this could change clinical approaches.
- 14:48Speaker 1: For example, wouldn't early intervention be key in future scenarios?
- 14:53Speaker 1: If the preliminary findings suggest that repeated mitochondrial injections might
- 14:58Speaker 1: help maintain visual function, wouldn't there be an incentive to
- 15:02Speaker 1: push for more preventive measures in patients at risk for
- 15:05Speaker 1: optic neuropathy?
- 15:07Speaker 2: Exactly. This brings up an interesting contradiction. On one hand,
- 15:11Speaker 2: you could argue that if this therapy is indeed effective,
- 15:15Speaker 2: doctors might emphasize preventive care to mitigate the risks of
- 15:19Speaker 2: optic nerve damage. On the other hand, if the results
- 15:22Speaker 2: aren't as robust, wouldn't the focus shift more towards developing
- 15:26Speaker 2: diagnostic tools to identify those at higher risk?
- 15:29Speaker 1: That's a great point. And let's consider the economic implications.
- 15:34Speaker 1: If the FDA starts allowing more expanded access protocols for
- 15:38Speaker 1: such procedures, how might that impact healthcare spending and insurance coverage?
- 15:43Speaker 1: Would we see more investment in this area, or might
- 15:46Speaker 1: there be resistance due to high costs?
- 15:48Speaker 2: Definitely. The financial aspects are significant. If the results continue
- 15:53Speaker 2: to look promising, expect a surge in both clinical trials
- 15:56Speaker 2: and commercial interest. However, with the current case highlighting the
- 16:00Speaker 2: complexities and uncertainties, Wouldn't the strategy involve a gradual rollout,
- 16:05Speaker 2: ensuring thorough testing and regulation?
- 16:07Speaker 1: Agreed. It'll be a balancing act. With the team working
- 16:11Speaker 1: on repeated intravitreal injections, how do you think this might
- 16:15Speaker 1: influence the future of mitochondrial therapy in ocular treatment? Would
- 16:20Speaker 1: this lead to more specialized clinics or a wider adoption
- 16:24Speaker 1: across general ophthalmology practices?
- 16:27Speaker 2: It's tough to say, Rachel, if future trials support the
- 16:30Speaker 2: initial results. we might see more specialized clinics emerge, focusing
- 16:35Speaker 2: on mitochondrial-based therapies. However, if early attempts show limitations, there
- 16:41Speaker 2: might be a push for a more integrated approach, perhaps
- 16:44Speaker 2: combining mitochondrial therapy with other existing treatments for a comprehensive
- 16:49Speaker 2: care model.
- 16:50Speaker 1: Fascinating. The landscape is certainly shifting, with the future of
- 16:54Speaker 1: treating optic neuropathy potentially transformed. How do you imagine these
- 16:59Speaker 1: breakthroughs impacting other retinal conditions like glaucoma or diabetic retinopathy?
- 17:04Speaker 2: That's a key insight. The principles behind mitochondrial therapy might
- 17:09Speaker 2: apply to other retinal conditions where cellular function is compromised.
- 17:13Speaker 2: For instance, if the therapy proves effective for optic neuropathy,
- 17:18Speaker 2: wouldn't that motivate further research into supporting retinal cells through
- 17:22Speaker 2: mitochondrial supplementation in conditions like glaucoma? where retinal ganglion cells
- 17:28Speaker 2: are also critically affected by metabolic stress.
- 17:31Speaker 1: Exactly. This interconnectivity is crucial. As we move forward, the
- 17:36Speaker 1: goal should be to leverage these findings for the broader
- 17:39Speaker 1: health of retinal cells, not just in optic neuropathy, but
- 17:43Speaker 1: across the spectrum of ocular diseases. And with that, I
- 17:47Speaker 1: think we have covered the strategic implications in a balanced
- 17:51Speaker 1: and practical way. That brings us to the end of
- 17:53Speaker 1: today's episode. Thank you so much for spending part of
- 17:56Speaker 1: your day with me. If you found this episode's tips
- 17:58Speaker 1: helpful and want to make sure you don't miss the
- 18:00Speaker 1: next conversation, please take a quick second to hit that
- 18:04Speaker 1: subscribe or follow button on whatever platform you are listening on.
- 18:08Speaker 1: It's a completely free way to support the show and
- 18:10Speaker 1: helps more people find us. This podcast is independently produced,
- 18:14Speaker 1: so if you are ever in a position where you
- 18:16Speaker 1: would like to help keep it running, we do accept
- 18:18Speaker 1: small donations. You can find a link right in the
- 18:21Speaker 1: episode description below to buy us a coffee, or contribute
- 18:24Speaker 1: what you can. Every bit genuinely helps. Take care of yourself,
- 18:28Speaker 1: stay balanced, and we will talk again soon.